Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
Sep 11, 2025, 08:35 ET The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health’s hepatology pipeline LAVAL, QC, and CUPERTINO, Calif., Sept. 11, 2025 /PRNewswire/ — Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) (“Bausch Health”), a global, diversified pharmaceutical company, today […]